search
Back to results

SodiUm SeleniTe Adminstration IN Cardiac Surgery (SUSTAIN CSX®-Trial). (SUSTAINCSX)

Primary Purpose

Heart Disease

Status
Unknown status
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
sodium selenite
Placebo
Sponsored by
Daren K. Heyland
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Heart Disease focused on measuring antioxidants, selenium, heart disease, cardiac surgery, perioperative

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Adult patients (>/=18 years of age)
  • Scheduled to undergo elective or urgent cardiac surgery with the use of cardiopulmonary bypass (CPB) and cardioplegic arrest that exhibit a high perioperative risk profile as defined by the presence of one or more of the following:

    • a) Planned valve surgery combined with CABG or multiple valve replacement/repair surgeries or combined cardiac surgical procedures involving the thoracic aorta; OR
    • b) Any cardiac surgery with a high perioperative risk profile, defined as a predicted operative mortality of ≥ 5% (EuroSCORE II).

Exclusion Criteria:

We will exclude patients who meet any of the following criteria:

  • Isolated procedures (CABG only or valve)
  • Known hypersensitivity to sodium-selenite or to any of the constituents of the solution.
  • Renal failure requiring dialysis at the point of screening.
  • Chronic liver disease as evidenced by a pre-operative total bilirubin >2 mg/dl or 34 umol/L.
  • Disabling neuropsychiatric disorders (severe dementia, severe Alzheimer's disease, advanced Parkinson's disease).
  • Pregnancy or lactation period.
  • Simultaneous participation in another clinical trial of an experimental therapy (co-enrolment acceptable in observational studies or randomized trials of existing therapies if permitted by both steering committees and local ethics boards).
  • Patients undergoing heart transplantation or preoperative planned LVAD insertion or complex congenital heart surgery.
  • Alternate contacts of investigators (required by German Regulatory Authorities).

Sites / Locations

  • Hamilton General Hospital
  • London Health Sciences Centre
  • University of Ottawa Heart Institute
  • Sunnybrook Health Sciences Centre
  • St. Michael's Hospital
  • Toronto General Hospital
  • Institut de cardiologie de Montreal
  • Sir Mortimer B. Davis Jewish General Hospital
  • McGill University Health Centre
  • Sacre Coeur
  • IUCPQ
  • Centre de recherche CIUSSS de l'Estrie CHUS
  • RWTH Aachen University Hospital
  • Klinik und Poliklinik für Anästhesiologie und Operative Intensivmedizin Universitätsklinikum Bonn
  • Universitätsklinikum Frankfurt
  • Klinik für Her- und Gefäßchirurgie Universitäts-Herzzentrum Freiburg
  • Klinik für Herz-, Kinderherz- und Gefäßchirurgie UKGM Giessen
  • University Medical Center Schleswig-Holstein
  • Klinik und Poliklinik für Herz- und Thoraxchirurgie Uniklinik Köln
  • Klinik für Anästhesiologie Universitätsmedizin Mainz
  • Klinik für Anästhesiologie Klinikum der Universität München
  • Klinik für Anästhesiologie, operative Intensivmedizin und Schmerztherapie Universitätsmedizin Münster, Zentralklinikum
  • Klinikum Oldenburg gGmbH Universitätsklinik für Anästhesiologie / Intensivmedizin / Notfallmedizin / Schmerztherapie

Arms of the Study

Arm 1

Arm 2

Arm Type

Placebo Comparator

Active Comparator

Arm Label

Placebo

sodium selenite

Arm Description

Normal saline will be administered to subjects intravenously pre-operatively, upon admission to the ICU, then daily up to post-operative day 10 or ICU discharge, whichever occurs first.

High-dose sodium-selenite will be administered to subjects intravenously: 1) pre-operatively (2000 ug); 2) upon admission to the ICU (2000 ug), 3) then daily (1000 ug) up to post-operative day 10 or ICU discharge, whichever occurs first.

Outcomes

Primary Outcome Measures

PODS free days + alive
Evaluate the PODS free days + alive as the primary outcome for the large-scale Phase III trial. We define PODS as the need for life-sustaining therapies (mechanical ventilation, vasopressor therapy, mechanical circulatory support, continuous renal replacement therapy, or intermittent hemodialysis).

Secondary Outcome Measures

30-Day Mortality
Mortality 30 days post-randomization.
Hospital Acquired Infections
To be evaluated up to 6 months post-randomization.
Perioperative hemodynamic profile
This includes: mean arterial blood pressure, cardiac power index, systemic vascular resistance, etc... To be assessed up to 6-months post-randomization.
Cardiovascular Complications
This includes: arrhythmias, cardiac arrest, infarction. To be assessed up to 6-months.
Duration of Mechanical Ventilation
To be assessed up to 6-months.
Incidence of post-operative delirium
Assessed by CAM-ICU score. To be assessed up to 6-months.
ICU Length of stay
To be assessed up to 6 months post-randomization.
Hospital Re-admission Rates
To be assessed up to 6-months post-randomization.
Hospital Length of stay
To be assessed up to 6 months post-randomization.
6-Month Survival
To be assessed at 6 months post-randomization.
Quality of Life
Health related quality of life to be assessed up to 6-months post-randomization.
Return to work
Assessed using a questionnaire to determine the patient's ability to return to their pre-operative working capabilities. To be assessed up to 6 months post-randomization.
6-minute walking test
6-minute walking distance

Full Information

First Posted
November 28, 2013
Last Updated
May 27, 2021
Sponsor
Daren K. Heyland
Collaborators
biosyn Arzneimittel GmbH, Queen's University, RWTH Aachen University
search

1. Study Identification

Unique Protocol Identification Number
NCT02002247
Brief Title
SodiUm SeleniTe Adminstration IN Cardiac Surgery (SUSTAIN CSX®-Trial).
Acronym
SUSTAINCSX
Official Title
SodiUm SeleniTe Adminstration IN Cardiac Surgery (SUSTAIN CSX®-Trial). A Multicentre Randomized Controlled Trial of High Dose Sodium-selenite Administration in High Risk Cardiac Surgical Patients
Study Type
Interventional

2. Study Status

Record Verification Date
May 2021
Overall Recruitment Status
Unknown status
Study Start Date
January 2015 (undefined)
Primary Completion Date
February 2021 (Actual)
Study Completion Date
July 2021 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Daren K. Heyland
Collaborators
biosyn Arzneimittel GmbH, Queen's University, RWTH Aachen University

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The aim of the investigators' research program is to investigate the effects of perioperative high dose selenium supplementation in high-risk cardiac surgical patients undergoing complicated open heart surgery. The investigators hypothesize that the therapeutic strategy tested in this randomized trial may contribute to a fewer complications, less organ injury and fewer deaths. Before the investigators conducted the large definitive trial, they conducted a pilot study to assess the feasibility of the protocol, and are rolling the pilot patients into the definitive trial.
Detailed Description
Over a million patients undergo open heart surgery annually and this number is likely to accelerate as the population ages and the prevalence of diabetes and cardiovascular disease continue to increase. Unfortunately, death, organ failure, and other serious complications are all too frequent following open heart surgery, especially in some high-risk patient populations. Selenium is a trace element that is important for many of the body's regulatory and metabolic functions especially during times of stress. International members of the study team have shown in a non-randomized study that high dose selenium supplementation was associated with improved clinical outcomes compared to a historical control group. The next step in this program of research is to conduct a randomized trial. The aim of this research program is to investigate the effects of perioperative high dose selenium supplementation in high-risk cardiac surgical patients undergoing complicated open heart surgery. The investigators hypothesize that the therapeutic strategy tested in this randomized trial may contribute to fewer complications, less organ injury and fewer deaths. The investigators propose to conduct a randomized, placebo-controlled, double-blind, multicentre definitive trial of 1400 patients across 20 sites in Germany and Canada, which will include the pilot study patients. An industry partner (Biosyn) will provide the product and some additional support for the European sites. Patients will be randomized to receive either a daily perioperative high-dose selenium or placebo until postoperative day 10 (maximum) or upon earlier discharge from ICU. If the hypothesis is proven true, and this simple, inexpensive nutrient reduces complications and improves recovery of patients undergoing cardiac surgery, there is the potential to dramatically change clinical practice and improve health outcomes.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Heart Disease
Keywords
antioxidants, selenium, heart disease, cardiac surgery, perioperative

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
1400 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Normal saline will be administered to subjects intravenously pre-operatively, upon admission to the ICU, then daily up to post-operative day 10 or ICU discharge, whichever occurs first.
Arm Title
sodium selenite
Arm Type
Active Comparator
Arm Description
High-dose sodium-selenite will be administered to subjects intravenously: 1) pre-operatively (2000 ug); 2) upon admission to the ICU (2000 ug), 3) then daily (1000 ug) up to post-operative day 10 or ICU discharge, whichever occurs first.
Intervention Type
Drug
Intervention Name(s)
sodium selenite
Other Intervention Name(s)
selenium
Intervention Description
All subjects will receive an IV bolus of 2000µg selenium within 30min after induction of anesthesia via the central venous catheter. After termination of surgery, immediately after admission to the ICU, all patients will receive a second bolus of 2000µg selenium. Then on every further morning during ICU-stay, patients will receive an IV bolus of 1000µg selenium via central or peripheral venous access until death, discharge from ICU to the ward, or for a maximum of 10 days.
Intervention Type
Drug
Intervention Name(s)
Placebo
Other Intervention Name(s)
NaCl 0.9%
Intervention Description
All patients will receive an IV bolus of normal saline (equals to 40ml prepared solution) within 30min after induction of anesthesia via the central venous catheter. After termination of surgery, immediately after admission to the ICU, all patients will receive a second bolus of normal saline accordingly. Then on every further morning during ICU-stay, patients will receive an IV bolus of normal saline via central or peripheral venous access until death, discharge from ICU to the ward (treatment may continue in a step down or intermediate care unit), or for a maximum of 10 days.
Primary Outcome Measure Information:
Title
PODS free days + alive
Description
Evaluate the PODS free days + alive as the primary outcome for the large-scale Phase III trial. We define PODS as the need for life-sustaining therapies (mechanical ventilation, vasopressor therapy, mechanical circulatory support, continuous renal replacement therapy, or intermittent hemodialysis).
Time Frame
30 Day
Secondary Outcome Measure Information:
Title
30-Day Mortality
Description
Mortality 30 days post-randomization.
Time Frame
30 Day
Title
Hospital Acquired Infections
Description
To be evaluated up to 6 months post-randomization.
Time Frame
30 day
Title
Perioperative hemodynamic profile
Description
This includes: mean arterial blood pressure, cardiac power index, systemic vascular resistance, etc... To be assessed up to 6-months post-randomization.
Time Frame
6 months
Title
Cardiovascular Complications
Description
This includes: arrhythmias, cardiac arrest, infarction. To be assessed up to 6-months.
Time Frame
6-months
Title
Duration of Mechanical Ventilation
Description
To be assessed up to 6-months.
Time Frame
6-months
Title
Incidence of post-operative delirium
Description
Assessed by CAM-ICU score. To be assessed up to 6-months.
Time Frame
6-months
Title
ICU Length of stay
Description
To be assessed up to 6 months post-randomization.
Time Frame
6-months
Title
Hospital Re-admission Rates
Description
To be assessed up to 6-months post-randomization.
Time Frame
6-months
Title
Hospital Length of stay
Description
To be assessed up to 6 months post-randomization.
Time Frame
6-months
Title
6-Month Survival
Description
To be assessed at 6 months post-randomization.
Time Frame
6-months
Title
Quality of Life
Description
Health related quality of life to be assessed up to 6-months post-randomization.
Time Frame
6-months
Title
Return to work
Description
Assessed using a questionnaire to determine the patient's ability to return to their pre-operative working capabilities. To be assessed up to 6 months post-randomization.
Time Frame
6-months
Title
6-minute walking test
Description
6-minute walking distance
Time Frame
up to 3 months
Other Pre-specified Outcome Measures:
Title
Laboratory outcomes
Description
To be assessed up to post-operative day (POD) 10 in patients who consent to this optional blood work. To assess the potential effects of supplementation on selenium levels, safety parameters and other mechanistic markers. Whole blood levels of selenium, selenoprotein P (Sel-P), antibodies against oxidized LDL, markers of inflammation (interleukin[IL]-6, IL-10, TNF alpha) and activity of glutathione-peroxidase (GPx) will be assessed to determine the efficacy of selenium supplementation in these patients.
Time Frame
POD 10

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Adult patients (>/=18 years of age) Scheduled to undergo elective or urgent cardiac surgery with the use of cardiopulmonary bypass (CPB) and cardioplegic arrest that exhibit a high perioperative risk profile as defined by the presence of one or more of the following: a) Planned valve surgery combined with CABG or multiple valve replacement/repair surgeries or combined cardiac surgical procedures involving the thoracic aorta; OR b) Any cardiac surgery with a high perioperative risk profile, defined as a predicted operative mortality of ≥ 5% (EuroSCORE II). Exclusion Criteria: We will exclude patients who meet any of the following criteria: Isolated procedures (CABG only or valve) Known hypersensitivity to sodium-selenite or to any of the constituents of the solution. Renal failure requiring dialysis at the point of screening. Chronic liver disease as evidenced by a pre-operative total bilirubin >2 mg/dl or 34 umol/L. Disabling neuropsychiatric disorders (severe dementia, severe Alzheimer's disease, advanced Parkinson's disease). Pregnancy or lactation period. Simultaneous participation in another clinical trial of an experimental therapy (co-enrolment acceptable in observational studies or randomized trials of existing therapies if permitted by both steering committees and local ethics boards). Patients undergoing heart transplantation or preoperative planned LVAD insertion or complex congenital heart surgery. Alternate contacts of investigators (required by German Regulatory Authorities).
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Daren K Heyland, MD
Organizational Affiliation
Queen's University
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Christian Stoppe, MD
Organizational Affiliation
RWTH Aachen University Hospital
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Bernard J McDonald, MD
Organizational Affiliation
Ottawa Heart Institute Research Corporation
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hamilton General Hospital
City
Hamilton
State/Province
Ontario
Country
Canada
Facility Name
London Health Sciences Centre
City
London
State/Province
Ontario
Country
Canada
Facility Name
University of Ottawa Heart Institute
City
Ottawa
State/Province
Ontario
Country
Canada
Facility Name
Sunnybrook Health Sciences Centre
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M4N3M5
Country
Canada
Facility Name
St. Michael's Hospital
City
Toronto
State/Province
Ontario
Country
Canada
Facility Name
Toronto General Hospital
City
Toronto
State/Province
Ontario
Country
Canada
Facility Name
Institut de cardiologie de Montreal
City
Montreal
State/Province
Quebec
ZIP/Postal Code
H1C1T8
Country
Canada
Facility Name
Sir Mortimer B. Davis Jewish General Hospital
City
Montreal
State/Province
Quebec
ZIP/Postal Code
H3T 1E2
Country
Canada
Facility Name
McGill University Health Centre
City
Montreal
State/Province
Quebec
Country
Canada
Facility Name
Sacre Coeur
City
Montreal
State/Province
Quebec
Country
Canada
Facility Name
IUCPQ
City
Quebec City
State/Province
Quebec
Country
Canada
Facility Name
Centre de recherche CIUSSS de l'Estrie CHUS
City
Sherbrooke
State/Province
Quebec
Country
Canada
Facility Name
RWTH Aachen University Hospital
City
Aachen
ZIP/Postal Code
52074
Country
Germany
Facility Name
Klinik und Poliklinik für Anästhesiologie und Operative Intensivmedizin Universitätsklinikum Bonn
City
Bonn
Country
Germany
Facility Name
Universitätsklinikum Frankfurt
City
Frankfurt
ZIP/Postal Code
60590
Country
Germany
Facility Name
Klinik für Her- und Gefäßchirurgie Universitäts-Herzzentrum Freiburg
City
Freiburg
Country
Germany
Facility Name
Klinik für Herz-, Kinderherz- und Gefäßchirurgie UKGM Giessen
City
Gießen
Country
Germany
Facility Name
University Medical Center Schleswig-Holstein
City
Kiel
Country
Germany
Facility Name
Klinik und Poliklinik für Herz- und Thoraxchirurgie Uniklinik Köln
City
Koln
Country
Germany
Facility Name
Klinik für Anästhesiologie Universitätsmedizin Mainz
City
Mainz
Country
Germany
Facility Name
Klinik für Anästhesiologie Klinikum der Universität München
City
München
Country
Germany
Facility Name
Klinik für Anästhesiologie, operative Intensivmedizin und Schmerztherapie Universitätsmedizin Münster, Zentralklinikum
City
Münster
Country
Germany
Facility Name
Klinikum Oldenburg gGmbH Universitätsklinik für Anästhesiologie / Intensivmedizin / Notfallmedizin / Schmerztherapie
City
Oldenburg
Country
Germany

12. IPD Sharing Statement

Citations:
PubMed Identifier
25169040
Citation
Stoppe C, McDonald B, Rex S, Manzanares W, Whitlock R, Fremes S, Fowler R, Lamarche Y, Meybohm P, Haberthur C, Rossaint R, Goetzenich A, Elke G, Day A, Heyland DK. SodiUm SeleniTe Adminstration IN Cardiac Surgery (SUSTAIN CSX-trial): study design of an international multicenter randomized double-blinded controlled trial of high dose sodium-selenite administration in high-risk cardiac surgical patients. Trials. 2014 Aug 28;15:339. doi: 10.1186/1745-6215-15-339.
Results Reference
derived

Learn more about this trial

SodiUm SeleniTe Adminstration IN Cardiac Surgery (SUSTAIN CSX®-Trial).

We'll reach out to this number within 24 hrs